Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| May 08, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP Clinical Ops & Data Mgmt | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP Clinical Ops & Data Mgmt | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| Nov 25, 2014 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 25,000 | $8.00 | 50,000 | |
| Jul 07, 2014 | SVP Business Planning & Dev | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 25,000 | |
| Jun 16, 2014 | Director, Chairman & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | $2.69 | 92,592 | |
| Mar 15, 2013 | Director | Open market or private purchase of non-derivative or derivative security | Form 4 | 25,000 | $3.40 | 45,000 | |
| Jan 19, 2011 | VP, Regulatory Affairs | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 25,000 | |
| Jan 19, 2011 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 25,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.